W Gaus

Universität Ulm, Ulm, Baden-Württemberg, Germany

Are you W Gaus?

Claim your profile

Publications (79)202.63 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: Although effective conventional therapies are available to treat basal cell carcinoma (BCC), undesirable side effects, including scarring, and in some cases permanent damage, often occur in problematic areas of the body, especially around the eyes, mouth, and cartilage of the nose and ears. In previous studies, intratumoural injection of recombinant interferon beta-1a (rIFN-beta-1a) has been shown to result in complete remission (CR) in 47% to 86% of patients with BETACC. The primary objective of the study was to determine the response rate to rIFN-beta-1a, in a larger BETACC patient population. Secondary objectives included evaluating the effect of tumour type/size on response as well as residues, cosmetic results, and relapse rate after CR. The safety profile of intratumoural rIFN-beta-1a in BETACC patients was also evaluated. This was an open-label, multicentre study involving 139 patients with BETACC (diameter between 5.0 and 20 mm). Intratumoural injections of rIFN-beta-1a (1.0 x 106 IU) were administered three times a week for 3 weeks. The response was determined 16 weeks after start of treatment and the status of patients was followed for up to 5 years. At 16 weeks, the response rate to intratumoural rIFN-beta-1a was 66.9% (95% CI, range 58.2-74.8%). There was no significant difference between the response rates for patients with solid or other BETACC tumour types. Similarly, tumour size did not significantly affect the response rate. The cosmetic result of treatment was rated as good or very good in 83% of responders. The relapse rate after CR was 4.5% (median follow-up 2 years). All patients showed local inflammatory reactions, which were generally considered to be the adverse drug reactions (ADRs). Systemic ADRs mostly consisted of flu-like symptoms and occurred in 32/139 patients. No ADRs were considered to be the serious. These results show that intratumoural injections of rIFN-beta-1a are effective in the treatment of BETACC in the majority of patients. In addition, rIFN-beta-1a is safe and generally well tolerated. rIFN-beta-1a represents an effective alternative treatment for BETACC.
    European journal of dermatology: EJD 11/2002; 12(6):558-61. DOI:10.2165/00003495-199550010-00005 · 1.99 Impact Factor
  • R Muche · F Rohlmann · G Büchele · W Gaus ·
    [Show abstract] [Hide abstract]
    ABSTRACT: New therapies in rehabilitation medicine have to be evaluated with clinical trials. For drug approval the methodology of clinical trials is standardized world wide and the results of these studies are widely accepted. This standard should be achieved in clinical trials in rehabilitation research, too. One of the standards is the existence of a control group, comparing the effect of the new intervention against controls. In addition, the investigational and control groups must be equal in terms of the structure of possible confounders. Randomisation is the best possibility to distribute the patients to the therapy-groups, confounders will be equally distributed by chance. Other procedures for assignment to the study groups can result in confounding and lead into biased results. In spite of these advantages, randomisation is not generally accepted in rehabilitation research up to now. There are some reservations, mostly ethical, organisational and methodological ones. However, randomised clinical trials should be conducted in rehabilitation research in order to obtain more convincing results. Our intention is to bring some input in this debate and to present basics and practical aspects of randomisation.
    Die Rehabilitation 11/2002; 41(5):311-9. · 0.73 Impact Factor
  • R. Muche · F. Rohlmann · G. Büchele · W. Gaus ·

    Die Rehabilitation 10/2002; 41(5):311-319. DOI:10.1055/s-2002-34568 · 0.73 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Für eine effiziente Rehabilitation ist es elementar, Patienten möglichst früh erkennen zu können, denen aller Wahrscheinlichkeit nach eine spätere Erwerbsunfähigkeit droht, um unterstützende Maßnahmen bereits während der Rehabilitationsmaßnahme oder in einer entsprechenden Nachsorge durchführen zu können. Fragestellung: Wie gut kann ein statistisches Prognosemodell, welches auf routinemäßig, während einer stationären Rehabilitationsmaßnahme erhobenen Befunden beruht, die längerfristige Erwerbsfähigkeit prognostizieren? Welche Merkmale aus dem zur Verfügung stehenden Datenbestand tragen zur Prognose über einen Zeitraum von 1–2 Jahren nach der Rehabilitation bei? Für 841 Patienten wurde aus Befunden der stationären Reha-Maßnahme die Wahrscheinlichkeit der Erwerbsfähigkeit errechnet und diese Vorhersage mit den seither eingetretenen Berentungen aus dem Versichertenkonto des regionalen Rentenversicherungsträgers (LVA Württemberg) verglichen. Das entwickelte Vorhersagemodell hat für die Zielgröße „Erwerbsfähigkeit 1–2 Jahre nach der Rehabilitation“ eine Sensitivität von ca. 75% und eine Spezifität von ca. 80%. Der positive prädiktive Wert beträgt 34%, der negative prädiktive Wert 97%. Somit kann durch ein Modell, welches ausschließlich auf Routinedaten beruht, eine praktisch brauchbare Vorhersage der längerfristigen Erwerbsföhigkeit bzw. Erwerbsunfähigkeit getroffen werden. Durch Hinzunahme von weiteren, aufwändiger zu erhebenden, krankheitsspezifischen Zusatzinformationen lässt sich die Zuverlässigkeit der Prognose sicherlich noch verbessern. For an efficient rehabilitation it is essential to identify patients as early as possible, who will probably loose their working capacity. Using this information supporting measures could be undertaken during inpatient rehabilitation or intensified aftercare. The purpose of this study was to show, how well a statistical model predicts long-term return to work, using routinely documented data during inpatient rehabilitation. In addition it was important to find, which variables out of the available data-pool contribute to the prediction for a time-period of 1–2 years. For 841 patients the probability of return to work was estimated using data from inpatient rehabilitation. The probability was compared with information from the regional pension insurance institute of Wuerttemberg about the actually granting of pension due to loss of working capacity. For the prognosis “working capacity 1–2 years after rehabilitation” the model obtains a sensitivity of 75% and a specificity of 80%. The positive predictive value amounts to 34%, the negative predictive value to 97%. Therefore it is possible to predict long-term return to work with a statistical model using routinely registered data only. The model could be further improved in appending further disease specific information.
    Journal of Public Health 08/2002; 10(3):229-241. DOI:10.1007/BF02956316 · 2.06 Impact Factor
  • R Muche · M Rösch · S Flierl · B Alt · E Jacobi · W Gaus ·
    [Show abstract] [Hide abstract]
    ABSTRACT: For efficient rehabilitation it is important to identify, as early as possible, the patients likely to be successfully returned to work after rehabilitation. The aim of this pilot study was to develop a statistical model for predicting this return as reliably as possible. The model uses only information readily available at the beginning of rehabilitation. A multiple regression analysis with backward elimination was used from a routine data base and identified 8 variables of prognostic value. The model offers a comfortable possibility to predict the probability of return to work of a patient on the basis of routinely registered data. The prognosis was found correct in 68% of those returning to work after rehabilitation (sensitivity) and in 80% of those who did not (specificity). Further work to improve the model for prognosis in rehabilitation research is considered reasonable.
    Die Rehabilitation 11/2000; 39(5):262-7. · 0.73 Impact Factor
  • R Muche · M Rösch · S Flierl · W Gaus ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Methodology of clinical studies is highly sophisticated in drug research. But clinical trials are also necessary to demonstrate efficacy and safety of rehabilitation treatment. The call for evidence based medicine has also reached rehabilitation. However, in rehabilitation medicine it is much more difficult to design and conduct clinical trials with a high methodological standard. Among the reasons are: A comparable control group is necessary because spontaneous healing and unspecific measures contribute to therapeutic success, too. But what could "placebo rehabilitation" look like? The masking of therapies (blinded studies) will hardly ever be possible. Therefore, it is more difficult to achieve the same treatment and observation for the treatment and control group. Treatments in rehabilitation take longer to become effective than a drug and maybe the success will disappear after some time. Therefore, long-term trials and follow-ups are necessary. Such studies are expensive, need a strong organisation, and drop-outs are unavoidable. An appropriate outcome variable does not always exist. "Return to work" is an important, reliable and valid variable, but it delivers only one bit of information per patient. As a consequence, smaller progress in rehabilitation can only be demonstrated with large sample sizes. Outcome variables based on time enable studies with reasonable sample sizes. Sometimes it is more difficult to obtain acceptance of randomisation in rehabilitation patients than in acute patients. Some rehabilitation hospitals have only recently begun to take an interest in controlled clinical trials, hence are not so experienced. Nevertheless, controlled clinical trials delivering convincing results are possible in rehabilitation medicine as well. But biometrical consultation is necessary e.g. for study design, study conduction and evaluation. Most important points are the methodology of the study design and its practicability. Especially in these topics rehabilitation physicians and biometrician have to cooperate.
    Die Rehabilitation 09/2000; 39(4):200-4. · 0.73 Impact Factor
  • J Högel · M Grabert · W Sorgo · S Wudy · W Gaus · E Heinze ·
    [Show abstract] [Hide abstract]
    ABSTRACT: In adult patients with type 1 diabetes good metabolic control was associated with an undesired weight gain. In the present report the possible association of HbA1c and body mass index (BMI) in children and adolescents with type 1 diabetes (IDDM) was investigated in a long-term retrospective study from 1976 to 1995. Further, the relationship between BMI on one hand and age, gender, duration of IDDM, the number of units of insulin used and the number of injections per day on the other hand were considered. Statistical analysis was performed using repeated measurements analyses of variance. The 208 girls and 201 boys were 5-17 years old and had diabetes for beyond one year. For analysis 2512 data sets, in part measurements on the same patient in the course of the disease, were available. In various statistical models, the results show that age, gender, the daily amount of insulin, and the HbA1c level (p<0.001-0.005) were associated with the BMI. Extremely high HbA1c levels coincided with a remarkably low BMI. Hence, in children and adolescents with IDDM it may be difficult to achieve a constantly good metabolic control accompanied by a normal body weight.
    Experimental and Clinical Endocrinology & Diabetes 01/2000; 108(2):76-80. DOI:10.1055/s-2000-5799 · 1.56 Impact Factor
  • Rainer Muche · M. Rösch · S. Flierl · B. Alt · E. Jacobi · W. Gaus ·

    Die Rehabilitation 01/2000; 39(5):262-267. DOI:10.1055/s-2000-7862 · 0.73 Impact Factor
  • Rainer Muche · Margrit Rösch · Steffen Flierl · Wilhelm Gaus ·

    Die Rehabilitation 01/2000; 39(4):200-204. DOI:10.1055/s-2000-5898 · 0.73 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The pharmacological inhibition of exocrine pancreatic secretion with the somatostatin analogue octreotide has been advocated as a specific treatment of acute pancreatitis. To investigate the efficacy of octreotide in acute pancreatitis in a randomised, placebo controlled trial. 302 patients from 32 hospitals, fulfilling the criteria for moderate to severe acute pancreatitis within 96 hours of the onset of symptoms, were randomly assigned to one of three treatment groups: group P (n=103) received placebo, while groups O1 (n=98) and O2 (n=101) received 100 and 200 microg of octreotide, respectively, by subcutaneous injection three times daily for seven days. The primary outcome variable was a score composed of mortality and 15 typical complications of acute pancreatitis. The three groups were well matched with respect to pretreatment characteristics. An intent to treat analysis of all 302 patients revealed no significant differences among treatment groups with respect to mortality (P: 16%; O1: 15%; O2: 12%), the rate of newly developed complications, the duration of pain, surgical interventions, or the length of the hospital stay. A valid for efficacy analysis (251 patients) also revealed no significant differences. This trial shows no benefit of octreotide in the treatment of acute pancreatitis.
    Gut 08/1999; 45(1):97-104. DOI:10.1136/gut.45.1.97 · 14.66 Impact Factor
  • A C Rodloff · P Kujath · B Lünstedt · W Gaus ·
    [Show abstract] [Hide abstract]
    ABSTRACT: The total costs of the hospital treatment of patients with secondary peritonitis were investigated with a prospective, randomized, multicenter study. Moreover, the cost-effectiveness of an initial therapy with Imipenem/Cilastatin was compared to selected alternative antibiotic regimens. Altogether 154 patients (77 Imipenem/Cilastatin group, 77 alternative group) that displayed Mannheim Peritonitis Scores between 16 and 26 (average 20.8) were analyzed. The average total cost of treatment was DM 11,140 per patient (range DM 2794-45,526). Patients receiving an initial therapy with Imipenem/Cilastatin incurred average costs of DM 10,455, while patients with alternative regimens caused average costs of DM 11,826. The difference between the two treatment groups was statistically significant (P = 0.037).
    Der Chirurg 11/1998; 69(10):1093-100; discussion 1100. · 0.57 Impact Factor
  • A. C. Rodloff · P. Kujath · B. Lünstedt · W. Gaus ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Im Rahmen einer prospektiven, randomisierten, multizentrischen Studie wurden die Gesamtbehandlungskosten von Patienten mit sekundärer Peritonitis erhoben. Dabei wurde die Kosteneffektivität einer initialen Behandlung mit Imipenem/Cilastatin mit der anderer ausgewählter Therapieregimes verglichen. Es wurden insgesamt 154 Patienten (77 Imipenem/Cilastatingruppe, 77 Alternativtherapiegruppe), die Mannheimer Peritonitisindices zwischen 16 und 26 (Mittelwert: 20,8) aufwiesen, in die Auswertung einbezogen. Die ermittelten durchschnittlichen Gesamtkosten betrugen 11.140 DM pro Patient (Einzelwerte lagen zwischen 2.794–45.526 DM). Patienten mit einer initialen Imipenem/Cilastatintherapie verursachten im Mittel Kosten in Höhe von 10.455 DM, während für die Patienten mit einer Alternativtherapie durchschnittliche Kosten von 11.826 DM ermittelt wurden; der Unterschied zwischen den Gruppenergebnissen ist statistisch signifikant (p = 0,037). The total costs of the hospital treatment of patients with secondary peritonitis were investigated with a prospective, randomized, multicenter study. Moreover, the cost- effectiveness of an initial therapy with Imipenem/Cilastatin was compared to selected alternative antibiotic regimens. Altogether 154 patients (77 Imipenem/Cilastatin group, 77 alternative group) that displayed Mannheim Peritonitis Scores between 16 and 26 (average 20.8) were analyzed. The average total cost of treatment was DM 11 140 per patient (range DM 2794–45 526). Patients receiving an initial therapy with Imipenem/Cilastatin incurred average costs of DM 10 455, while patients with alternative regimens caused average costs of DM 11 826. The difference between the two treatment groups was statistically significant (P = 0.037).
    Der Chirurg 10/1998; 69(10):1093-1099. DOI:10.1007/PL00002565 · 0.57 Impact Factor
  • J Högel · A C Rodloff · G Büchele · W Gaus ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Economic studies in medicine are intended to investigate costs, associated with a particular problem dealing with the indication, diagnosis or therapy, for instance, whether the high costs involved in a highly intensive or innovative therapy could be balanced by the eventual savings made, due to the shorter periods of treatment. In such situations a randomized controlled trial is necessary to find out which therapy or which therapeutical strategy is least expensive in the long run. Economic studies do, however, present some specific problems. Making a list of all the cost-relevant treatment items can be very laborious, but the use of flat rates and lump sums alone cannot lead to a complete cost analysis. Often, costs between hospitals vary more than between treatment regimens. Early and sudden deaths incur low costs and may bias the results. Furthermore, costs are distributed with a long and heavy upper tail including extreme outliers. This does, in fact, complicate the estimation of the sample size. In this article, these problems are outlined and, with the help of the data obtained from two randomized economic trials in health care, solutions are proposed and discussed.
    Methods of Information in Medicine 01/1998; 37(1):53-8. · 2.25 Impact Factor
  • Source
    E Lotterer · J Högel · W Gaus · W E Fleig · J Bircher ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Quantitative liver function tests such as the determination of galactose elimination capacity (GEC) or the aminopyrine breath test (ABT) may have the potential to serve as refined entry criteria and surrogate markers for end-points in controlled clinical trials. The magnitude of a statistically detectable difference in test results and the period of observation required to document such a difference must be known to properly design such trials. Therefore, we explored retrospectively the time course of changes in GEC and ABT and their reproducibility from a cohort of patients with alcoholic cirrhosis followed for 12 to 42 months, with a median of 34 months. In 15 patients who stopped drinking, GEC improved significantly by 0.64 mg/min/kg within 1 year (mean; 95% confidence interval [CI]: 0.42; 0.86). In contrast, it deteriorated by 0.53 mg/min/kg within 1 year (95% CI: 0.32; 0.74) in another 17 patients who continued to drink (P < .01). The residual standard deviation of the changes in GEC with respect to the patients' initial values was 0.43 mg/min/kg (95% CI: 0.32; 0.52). In addition, ABT improved significantly by 0.14% dose x kg/mmol CO2 (95% CI: 0.09; 0.18) in the abstinent group, and deteriorated by 0.09% dose x kg/mmol CO2 (95% CI: 0.06; 0.13) in the nonabstinent group (P < .01). The residual standard deviation in the above sense for ABT was 0.08% dose x kg/mmol CO2 (95% CI: 0.06; 0.10). These data indicate that clinical trials with a sample size of n = 20 in each group must achieve absolute differences (ADs) in GEC of 0.6 mg/min/kg and of 0.7 mg/min/kg to reach statistical significance at the 5% and 1% level, respectively. In the present study, a period of 11 and 12 months was necessary to observe such differences. The corresponding results for the ABT are 0.11% dose x kg/mmol CO2 (9 months of follow-up; 5% level) and 0.13% dose x kg/mmol CO2 (11 months of observation; 1% level), respectively. Provided that patients with liver diseases treated with drugs are similar to the abstinent and nonabstinent patients with alcoholic liver disease investigated in this study, such numbers could serve for the planning of controlled clinical trials, in which the control group is likely to deteriorate and the treated group is expected to improve. Trials based on GEC or ABT would require only 37 or 30 patient years of observation compared with a median of 444 patient years (range, 50-2,100 patient years) reported for various published controlled clinical trials using survival analysis.
    Hepatology 12/1997; 26(6):1426-33. DOI:10.1002/hep.510260609 · 11.06 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To confirm significant improvement of the skin score in systemic sclerosis by treatment with interferon gamma in a larger group of patients and to investigate on a molecular level the influence of interferon gamma on collagen type I messenger RNA expression. Open, noncontrolled multicenter study. Five outpatient clinics specializing in the care of systemic scleroderma. Thirty-two patients suffering from the diffuse or limited form of systemic sclerosis and progressive disease were recruited; 20 patients finished the study. Each patient received interferon gamma, 50 micrograms subcutaneously 3 times a week for 1 year. Skin score, collagen type I messenger RNA in skin biopsy specimens. The patients who completed the study showed an unchanged median skin score after 1 year of therapy. In addition, similar collagen type I messenger RNA levels were detected in skin biopsy specimens taken from involved skin before and after therapy in these patients. Treatment of systemic scleroderma with interferon gamma is associated with stabilization of the skin score and lack of worsening of visceral involvement.
    Archives of Dermatology 06/1997; 133(5):609-13. DOI:10.1001/archderm.133.5.609 · 4.79 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We conducted a randomized, placebo-controlled, double-blind clinical trial in order to determine the efficacy of classical homeopathic therapy in patients with chronic headaches. After 6 weeks of baseline observation, patients received either the prescribed individualized homeopathic medication or an indistinguishable placebo for 12 weeks. Outcome parameters were headache frequency, duration, and intensity, measured daily by diary. Use of medication for acute headache was also monitored. Of the 98 patients in the sample, 37 were randomized to receive placebo, 61 received individualized homeopathic remedies. Groups were comparable at the beginning of the treatment. The median age was 48.5 years; 76% suffered from migraine, 51% from tension-type headaches, and 94% were previously treated for headache. The median headache frequency was 3 days a week. Headaches were present for 23 years (median). In both groups, patients showed an improvement of one headache day less per month. The use of medication for acute headache was reduced. The headache frequency of 21 patients was reduced by more than 40%. Thirty-nine patients either did not improve or experienced aggravations. There was no significant difference in any parameter between homeopathy and placebo.
    Cephalalgia 05/1997; 17(2):119-26; discussion 101. DOI:10.1016/S0007-0785(98)80027-6 · 4.89 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Localized scleroderma is characterized by circumscribed fibrotic plaques and may progress to widespread skin involvement and fibrosis. Interferon gamma (IFN-gamma) has been shown to be a potent inhibitor of collagen synthesis and of the migration and proliferation of dermal fibroblasts. Our purpose was to determine whether IFN-gamma is effective in the treatment of localized scleroderma. A double-blind, randomized, placebo-controlled, multicenter study was conducted. Twenty-four patients with progressive lesions received 100 micrograms of IFN-gamma or placebo subcutaneously on 5 consecutive days for 2 weeks followed by 100 micrograms of IFN-gamma or placebo once weekly for 4 weeks. Thereafter patients were observed for 18 weeks. To determine whether improvement could be related to an altered level of collagen messenger RNA (mRNA), biopsy specimens were taken from uninvolved and involved skin before and after therapy. The patients treated with IFN-gamma or placebo showed no significant difference in size or fibrosis of lesions or collagen type I mRNA synthesis. However, a reduction in the number of new lesions was observed in the IFN-gamma-treated group. The biopsy specimens obtained from involved skin showed a moderate increase of type I collagen and a significant decrease in the small proteoglycan decorin mRNA levels. The results indicate that IFN-gamma is ineffective in the treatment of localized scleroderma, but may inhibit the development of new lesions.
    Journal of the American Academy of Dermatology 04/1997; 36(3 Pt 1):433-5. DOI:10.1016/S0190-9622(97)80221-6 · 4.45 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of the double-blind, placebo controlled study was to find out whether the intralesional injections of recombinant IFN-beta will result in regression of basal cell carcinoma (BCC) after 3 times weekly application of 1 MU for 3 weeks. The results were evaluated 16 weeks after the first injection and the follow-up lasted up to 2 years. Histologically in confirmed regression of BCC occurred in 7/15 (47%) of the evaluable patients treated with rIFN-beta, while all tumors receiving placebo persisted. 29% of the patients receiving interferon developed slight systemic side effects. The treatment with interferon induced a distinct inflammation at the injection site in 11/16 patients, while in only 4/18 patients receiving placebo. Interferon beta was effective alternative for the treatment of BCC and is well tolerated at the applied dose.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The comparison of the three instruments (QLQ-C30, SF-36, QWB-7) of HRQL research was made to investigate the question whether these instruments provide comparable results when tested in a population of patients with haematologic malignancies and solid tumours.For this purpose a comprehensive description of the three instruments considering general principles, construction of scales and items and scoring procedures was conducted. This can be taken as a prerequisite for comparing instruments which are used as health-outcome measures.The study showed that the comparability of the two questionnaires QLQ-C30 and SF-36 was generally better than these questionnaires with the QWB-7 interview. The interview does not identify poor health conditions. Although the QLQ-C30 and the SF-36 contribute comparable information, specifically for the Physical Functioning scale and Symptom scales Pain and Fatigue, important differences have to be considered. Only the QLQ-C30 contains the important question about ‘overall quality of life’. The results of the dimension ‘Role Functioning’ are not comparable because the SF-36 differentiates between Physical and Emotional Role Functioning whereas the QLQ-C30 constructs Role Functioning as a single dimension.All three instruments have a limited scope of applicability for a hospitalized population of patients with haematologic malignancies or solid tumours. Based on the study results further modification and refinement of these instruments are recommended for this population.
    Psycho-Oncology 06/1996; 5(2):103 - 117. DOI:10.1002/(SICI)1099-1611(199606)5:2<103::AID-PON221>3.0.CO;2-W · 2.44 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The present study assessed the total cost involved in the therapy of nosocomial pneumonia. Cost for patients receiving Imipenem as initial antibiotic therapy was compared with that for patients treated by selected alternative regimens. Secondary objectives included the evaluation of fever days, days of antibiotic therapy, days at ICU and days of overall hospitalisation required for the treatment of the nosocomial pneumonia for both methods of treatment. A prospective randomised open study involving multiple study sites was conducted. Total cost, efficacy and safety of an initial therapy with Imipenem were compared to results achieved with selected other antibiotic regimens. Altogether 109 patients were enrolled into the study; 85 patients could be assessed. Both treatment methods showed equal clinical efficacy. Total cost of the therapy of nosocomial pneumonia for all patients was in the range between 1,616 DM and 82,141 DM, the arithmetic mean was calculated to be 11,307 DM and the median was found to be 6,507 DM. Imipenem-treated patients incurred lower cost (median 5,649 DM, mean 10,009 DM) than patients treated with other antibiotics (median 9,334 DM, mean 12,701 DM). The total cost of treatment of nosocomial pneumonia was lower for Imipenem-treated patients than for patients receiving initially other selected antibiotic regimens. The savings are apparently due to a faster recovery of the patients resulting in reduced duration of therapy. The study shows that assessment of cost of therapy per day might be misleading in the economic analysis of antimicrobial chemotherapy.
    ains · Anästhesiologie · Intensivmedizin 05/1996; 31(3):172-80. · 0.44 Impact Factor

Publication Stats

1k Citations
202.63 Total Impact Points


  • 1977-2002
    • Universität Ulm
      • • Institute of Biophysics
      • • Department of Internal Medicine
      Ulm, Baden-Württemberg, Germany
  • 1996-1998
    • University of Leipzig
      • Institut für Medizinische Mikrobiologie und Infektionsepidemiologie
      Leipzig, Saxony, Germany
  • 1997
    • Martin Luther University of Halle-Wittenberg
      Halle-on-the-Saale, Saxony-Anhalt, Germany
    • University of Cologne
      • Department of Dermatology and Venerology
      Köln, North Rhine-Westphalia, Germany
  • 1992
    • Institut für klinische Pharmakologie
      Stuttgart, Baden-Württemberg, Germany